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Abstract
Tumor angiogenesis is an important target for cancer therapy, with most current therapies designed to block the
VEGF signaling pathway. However, clinical resistance to anti-VEGF therapy highlights the need for targeting
additional tumor angiogenesis signaling pathways. The endothelial Notch ligand Dll4 (delta-like 4) has recently
emerged as a critical regulator of tumor angiogenesis and thus as a promising new therapeutic anti-angiogenesis
target. Blockade of Dll4-Notch signaling in tumors results in excessive, non-productive angiogenesis with resultant
inhibitory effects on tumor growth, even in some tumors that are resistant to anti-VEGF therapies. As Dll4 inhibitors
are entering clinical cancer trials, this review aims to provide current perspectives on the function of the Dll4-Notch
signaling axis during tumor angiogenesis and as a target for anti-angiogenic cancer therapy.
Introduction
The concept that solid tumors require the growth of
new blood vessels (angiogenesis) for oxygen and nutri-
ent supply, first proposed by Folkman 40 years ago [1],
is now solidly accepted and has spurred substantial
efforts to develop anticancer therapeutics that interfere
with tumor angiogenesis. Many of the angiogenic sig-
naling pathways necessary for embryonic development
are reactivated during tumor angiogenesis, and as such
represent targets for anti-angiogenic cancer therapy.
VEGF (vascular endothelial growth factor) is a primary
endothelial cell growth factor, and blockade of the
VEGF signaling pathway is now a clinically approved
and widely used therapy for cancer. However, inherent
or acquired resistance to anti-VEGF therapy is fre-
quently observed in tumors, thus illustrating the need
for targeting additional angiogenesis pathways to fully
exploit the promise of anti-angiogenic cancer therapy.
Notch signaling has recently emerged as a critical regu-
lator of developmental and tumor angiogenesis. Notch
signaling in both endothelial and smooth muscle cells
appears to provide critical regulatory information to
these cells downstream of the initiating signal induced
by VEGF. In particular, the Notch ligand Dll4 (delta-like
4) has been identified as a promising new target
in tumor angiogenesis in preclinical studies.
Pharmacological Dll4 inhibitors have been developed
and are entering clinical trials for solid tumors. This
review aims to provide current perspectives on the
function of Dll4-Notch signaling axis during tumor
angiogenesis and on mechanisms and applications of
targeting this pathway for cancer therapy.
The Delta/Jagged-Notch signaling pathway
The Notch pathway is an evolutionary conserved
signaling system that regulates cell fate specification,
tissue patterning and morphogenesis by modulating
cell differentiation, proliferation, apoptosis and survival
[2-4]. In mammals, the core components of the path-
way include five canonical DSL (Delta, Serrate, Lag2)
l i g a n d s( c a l l e dD l l 1 ,3 ,4 ,a n dJ a g g e d 1a n d2 )a n df o u r
single-pass transmembrane receptors (Notch1-4). Since
the DSL ligands are membrane-bound, the Notch path-
way relies on direct cell-cell interactions for signal
generation. Ligand binding to the extracellular domain
of Notch triggers the proteolytic activation of the
receptor. Juxtamembrane region cleavage of Notch by
ADAM metalloproteinase is followed by g-secretase
complex-mediated cleavage and generation of the
Notch intracellular domain (NICD). NICD then trans-
locates to the nucleus, where it interacts with the
RBPJ/CSL transcription factor and induces the expres-
sion of Notch target genes such as the basic helix-
loop-helix proteins Hes and Hey. * Correspondence: Gavin.Thurston@regeneron.com
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY
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Functional studies in mice, zebrafish and cultured
endothelial cells have demonstrated a critical role for
Notch signaling during formation of the vascular system
(for recent comprehensive reviews see [5-7]). Of the
four Notch receptors, Notch1 and Notch4 are expressed
by endothelial cells [8]. Gene targeting studies in mice
have demonstrated that Notch1 is the primary func-
tional Notch receptor during developmental angiogen-
esis [9]. Except for Dll3, expression of all Notch ligands
has been detected in endothelial cells [5]. Dll4 is the
first Notch ligand to be expressed during mouse devel-
opment, and Dll4 transcripts were detected in most
capillary beds and arterial vessels [10,11]. Lack of a sin-
gle Dll4 allele in mice leads to early embryonic lethality
characterized by severe defects in arterial differentiation
and vascular remodeling [12-14].
A clearer picture of Dll4 function during vascular
morphogenesis has emerged from subsequent studies
demonstrating that one function of Dll4 is to regulate
the specification of endothelial cells into tip and stalk
cells during angiogenic sprouting [15-20]. Dll4 is
induced in endothelial tip cells of angiogenic sprouts
in response to VEGF [15,17,21] and activates Notch in
adjacent stalk cells. Mosaic analysis has demonstrated
that Notch is required cell-autonomously for stalk cell
specification by actively repressing tip cell phenotypes
[15]. Loss of Dll4 expression leads to dramatically
increased capillary sprouting and branching as a result
of excessive tip cell formation and endothelial prolif-
eration. Thus Dll4-Notch signaling functions as a regu-
lator of angiogenesis downstream of VEGF. The loss of
Notch signaling is associated with an increase in VEGF
receptor (VEGFR)-2 and VEGFR-3 expression in stalk
cells [20,22,23], indicating that Notch can provide
negative feedback to reduce the activity of the VEGF/
VEGFR axis.
Dll4-Notch signaling in tumor angiogenesis
Studies in humans and mice have demonstrated that
Dll4 is strongly expressed by the tumor vasculature
and generally not by the tumor cells themselves. In
various mouse models, strong Dll4 expression was
observed in the majority of tumor vessels, contrasting
with significantly lower vascular expression in adjacent
normal tissues [11,13,24]. Paralleling vascular develop-
ment, Dll4 expression in tumor vessels appears to be
directly regulated by VEGF; thus Dll4 expression levels
in tumors have been found to correlate with those of
VEGF [24,25]. In humans, Dll4 expression was ana-
lyzed in tumors from kidney, bladder, colon, brain and
breast [11,25-29]. Robust Dll4 expression was observed
specifically in the tumor vasculature in all of these
tumor types, whereas Dll4 expression was low to
undetectable in the vasculature of adjacent normal tis-
sue. For example, Dll4 expression in renal clear cell
tumors was confined to the vasculature and detected
at nine-fold higher levels than in normal kidney
[11,29]. Dll4 expression was generally not observed in
the tumor parenchyma, although sporadic tumor cell
expression was detected in colorectal and brain tumor
samples [27,28]. Interestingly, although most colorectal
and breast tumors showed positive Dll4 expression in
tumor vessels, some tumors were negative. Further, at
least in the case of breast cancer, the degree of Dll4
expression correlated with outcome: tumors with high
Dll4 in the vasculature progressed more rapidly [26].
More work is needed to understand the factors that
regulate Dll4 expression in tumors and to extend the
connection between Dll4 expression and tumor
progression.
Consistent with its role in endothelial tip/stalk cell
specification during development, inhibition of Dll4-
Notch signaling caused increased vascular density and
vascular sprouting in tumors [24,28,30,31]. Surprisingly,
this vascular overgrowth phenotype resulted in tumor
growth inhibition in a variety of human and rodent
tumor models [24,30,31]. Perfusion studies demon-
s t r a t e dt h a tt h eh y p e r s p r o u ting tumor vasculature was
non-functional and consequently, anti-Dll4-treated
tumors exhibited increased levels of hypoxia. Thus,
blockade of Dll4-Notch signaling leads to tumor vessel
“abnormalization” (i.e. the formation of a hypersprout-
ing, non-functional vasculature) with resultant growth
inhibitory effects on tumors [32].
Gene targeting studies suggest that Notch1 is the pri-
mary Notch receptor during developmental angiogenesis
[9]. Therefore it appears plausible that Notch1 is also
the predominant mediator of Dll4-Notch signaling in
the tumor vasculature, although Notch4 has also been
described as a receptor specifically expressed by
endothelial cells. Recently generated Notch1-specific
inhibitory antibodies exhibited tumor vessel effects simi-
lar to those seen following blockade to Dll4 [33]. Addi-
tional Notch receptor-specific reagents or new
conditional genetic mouse models will be instrumental
for delineating the relative contribution of Notch1 and
Notch4 to tumor angiogenesis.
Notch ligands other than Dll4 may also affect tumor
angiogenesis. For instance, Jagged1 expression was
detected in clinical breast cancer samples [34,35], while
pro-angiogenic, paracrine functions for Jagged1 in head
and neck squamous cell carcinoma have also been sug-
gested [36]. Similarly, Jagged1 tumor angiogenesis-pro-
moting effects were inferred in a mouse mammary
tumor model [37]. Of note in this context, opposing
effects of Dll4 and Jagged1 on endothelial sprouting
were recently reported in the retina angiogenesis model
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tumor angiogenesis in a fibroblast tumor model [39].
Mechanisms of Dll4-Notch inhibition on tumor vessels
Blockade of Dll4-Notch resulted in tumor growth inhibi-
tion in a variety of human and rodent tumor models
associated with the formation of a non-functional,
hypersprouting tumor vasculature [24,30-32]. Perfusion
studies demonstrated that the hypersprouting tumor
vasculature was non-functional, rendering the tumors
more hypoxic (tumor vessel abnormalization) [32].
However the precise mechanisms underlying the rapid
reduction of tumor perfusion following Dll4-Notch inhi-
bition are not fully understood. Indeed, it is not known
whether endothelial cell hypersprouting can lead to
reduced tumor perfusion and is thus a primary
upstream event, or whether an initial loss of tumor ves-
sel perfusion leads to hypersprouting (Figure 1).
In one set of studies, reduced pericyte coverage and
increased vascular leakage were observed in tumors
treated with Dll4-Notch inhibitors [40,41]. Such an
increase of vascular leakiness associated with impaired
vascular integrity may explain a rapid decrease in
tumor perfusion. Another possibility is that the abnor-
malized network as a whole loses the organization or
vaso-regulation necessary to support adequate perfu-
sion [30,32].
Alternatively, it is plausible that initiation of hyper-
sprouting structures that are devoid of lumens would
result in a loss of perfusion. Endothelial lumen forma-
tion is an essential step during vascular morphogenesis,
and several mechanisms have been described for lumen
formation in different vascular beds, including the coa-
lescence of vacuoles within endothelial cells and the api-
cal surface specialization between adjacent endothelial
cells [42,43]. Tumor vessel obstruction by intraluminal
endothelial cells was recently reported in response to g-
secretase inhibitor treatment in both an orthotopic renal
cell carcinoma and a VEGF-driven rabbit hind limb
angiogenesis model [41]. In contrast, however, a recent
study demonstrated reduced microvascular occlusion
and the modulation of vasoconstriction following inhibi-
tion of Dll4-Notch signaling during post-angiogenic
remodeling in retinal angiogenesis [44].
While it is suggested that endothelial hypersprouting
may lead to disorganized cellular organization and ulti-
mately vessel obstruction, this phenomenon is also
reminiscent of the loss of cell polarity phenotype
recently reported in endothelial b1i n t e g r i nm u t a n t s
[45]. Endothelial cell polarization, linked to the specia-
lized apical-basal distribution of cell adhesion mole-
cules and their interaction with the Par polarity
complex [42,43], is a necessary step for the formation
of a patent vascular lumen. For example, loss of
endothelial b1 integrin results in the loss of Par3
expression and the mislocalization of cell adhesion
proteins Claudin-5, PECAM-1, VE-cadherin and CD99
specifically in arteries [45]. The activation of b1i n t e g -
rin by Dll4-Notch1 in a CSL-independent manner [46]
suggests a possible link between Notch signaling and
endothelial cell polarity.
CCM1 is another emerging regulator of endothelial
cell polarization and lumen formation [47]. CCM1
interacts with VE-cadherin and directs adherens junc-
tion organization, distribution and association with the
Par polarity complex in cultured endothelial cells and
in human cerebral cavernous malformation (CCM)
lesions [47]. CCM1 interacts with the intracellular pro-
tein ICAP1, which in turn binds specifically to b1
integrins [48]. Both CCM1 and ICAP regulate endothe-
lial cell quiescence and angiogenic sprouting by acti-
vating Dll4-Notch signaling [49]. Thus, it is possible
that some of the cell polarizing functions of CCM1 are
mediated by Notch signaling. Based upon these asso-
ciations, further analysis of the expression and distri-
bution of polarity markers in the context of Dll4-
Notch inhibition may provide additional evidence for a
role for Notch signaling in regulating lumen formation
and/or maintenance.
Dll4 
blockade  
Increased  
vessel sprouting 
Poorly perfused tumor 
Vascularized growing tumor 
Decreased 
vascular perfusion 
Tumor vessel  
abnormalization 
? ? 
Figure 1 Effects of Dll4-Notch inhibition on tumor
angiogenesis. Blockade of Dll4-Notch signaling in endothelial cells
leads to tumor vessel abnormalization characterized by increased
tumor vessel sprouting and decreased vascular perfusion. It is
currently not clear whether hypersprouting leads to decreased
tumor perfusion (left hand axis) or decreased perfusion leads to
hypersprouting (right hand axis), or whether both occur in parallel.
The overall effect of Dll4-Notch blockade is decreased tumor
perfusion and reduced tumor growth.
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pathways
Studies in various model systems have established that
the VEGF pathway can regulate the expression of Notch
signaling components [29,50]. Up-regulation of Dll4
expression by VEGF has been demonstrated in cultured
endothelial cells and in endothelial tip cells in the retina
angiogenesis model [17,20,29,30,51]. Similarly, strong
expression of Dll4 on the growing front of tumor ves-
sels and VEGF regulation of Dll4 in tumors has been
documented [24]. Conversely, down-regulation of
VEGFR2 and VEGFR3 expression following Notch acti-
vation was found in cultured endothelial cells and
endothelial stalk cells [20,22,52]. Down-regulation of
VEGFR2 and/or VEGFR3 h a sb e e np r o p o s e da sa
mechanism to reduce endothelial proliferation and
migration and to permit local differentiation of cells
within a zone of VEGF-driven angiogenesis [7]. These
finding suggest that Notch can provide negative feed-
back to reduce the activity of the VEGF/VEGFR2/
VEGF3 axis during angiogenic sprouting (Figure 2). The
emerging picture is that VEGF acts as a central driver
of angiogenesis, while Notch signaling helps to coordi-
nate the response appropriately [53].
Although this model also applies to tumor angiogen-
esis, additional complexities appear to exist in the
tumor microenvironment [50]. For instance, the fact
that potent combination effects are observed for the
simultaneous blockade of Dll4 and VEGF [30] is difficult
to reconcile with a simple linear negative feedback
model. Pathways other than VEGF, such as FGF, Angio-
poietin-1/Tie2, Wnt, inflammatory cytokines, extracellu-
lar matrix components or Notch signaling itself were
also shown to induce the expression of Dll4 in endothe-
lial cells. Thus, it is plausible that some of these addi-
tional factors also act upstream of Dll4 in the tumor
environment [30,54-58] (Figure 2).
EphrinB2 has been identified as key downstream tar-
get gene of Dll4-Notch in cultured endothelial cells
and during endothelial specification towards the arter-
ial fate in mouse and zebrafish [6]. More recently,
EphrinB2 regulation of VEGFR2 endocytosis and sig-
naling in endothelial tip cells upstream of Dll4-Notch
was reported [59,60] (Figure 2). Targeted disruption of
EphrinB2 results in early embryonic lethality due to
angiogenic remodeling defects [61,62]. It is of great
interest to determine how EphrinB2 affects the tumor
vasculature in the presence of high levels of VEGF.
Suppression of EphrinB2 signaling using soluble
EphrinB2-Fc in a subcutaneous squamous cell carci-
noma model phenocopied the effects of Dll4 blockade,
in particular, reduced tumor growth accompanied by
the induction of non-productive angiogenesis [63],
suggesting that EphrinB2 acts as a downstream
mediator of Dll4/Notch function. Conversely, targeted
inactivation of EphrinB2 PDZ-dependent reverse sig-
naling led to decreased vascularization and reduced
endothelial sprouting, that is, the normalization of the
tumor vasculature, in an orthotopic glioma model
VEGF 
VEGFR  EphrinB2 
Dll4 
Notch  No otc Notc Notc Notc
VEGFR 
EphrinB2 
apelin, ESM-1 
Ang2, Wnt 
? 
? 
FGF, 
Wnt, 
Ang1
 
 
Figure 2 I n t e r a c t i o no ft h eD e l t a - N o t c ha x i sw i t ho t h e r
signaling pathways in endothelial cells. Solid lines denote
protein-protein interactions, while dashed lines indicate
transcriptional regulation. Binding of VEGF to VEGF receptors
(VEGFR2) results in the transcriptional up-regulation of Dll4. Dll4-
mediated activation of the Notch receptor on an adjacent
endothelial cell leads to the transcriptional repression of VEGFR
expression. EphrinB2 is a Dll4-Notch target gene, but also acts
upstream of Dll4-Notch signaling as a regulator of VEGFR
endocytosis and signaling. Other putative signaling pathways
downstream of Dll4-Notch include apelin, ESM-1, Ang2 and Wnt,
while FGF, Wnt and Ang1 are potential upstream activators of Dll4
expression.
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soluble EphB4-Albumin resulted in reduced tumor
vascularization in the RIP1-Tag2 model of pancreatic
islet carcinogenesis [40], consistent with an inhibitory
activity on VEGF signaling and a function upstream of
Dll4. It is possible that EphrinB2 inhibition exhibits
specific effects depending on the tumor model or
reagent. Further studies are warranted to elucidate
EphrinB2 function during tumor angiogenesis, particu-
larly in the context of anti-VEGF and/or anti-Dll4
combination therapies.
Several tip cell-enriched genes have recently been
identified in the mouse retina which may yield clues to
which signaling pathways mediate the effects of Dll4-
Notch blockade on the tumor vasculature [64,65]. Of
particular interest are the secreted molecules ESM-1,
angiopoietin-2 and apelin. Binding of these factors to
their cognate receptors on stalk cells and the regulation
of retinal angiogenesis and endothelial proliferation by
the apelin/APJ signaling axis were demonstrated [64].
Additionally the induction of Wnt signaling activity in
endothelial cells via the Notch target gene Nrarp was
recently shown [66]. The functional significance of these
pathways in the context of Dll4-Notch blockade in
tumors remains to be determined.
Therapeutic Inhibition of Dll4-Notch signaling during
tumor angiogenesis
Pharmacological targeting of Dll4-Notch signaling in
preclinical tumor models has been achieved by several
different mechanisms including anti-Dll4 antibodies,
DNA vaccination, soluble Dll4-Fc and Notch-Fc decoys,
Notch antibodies, and g-secretase inhibitors
[24,28,30,31,37,41,67,68]. Unlike g-secretase inhibitors
that broadly block all Notch signaling, specific targeting
of Dll4 with anti-Dll4 antibodies did not induce overt
gastrointestinal toxicity and has thus emerged as an
attractive target for anti-angiogenic cancer therapy
[30,69]. Consequently, anti-Dll4 antibodies have recently
entered clinical trials for the treatment of advanced
solid malignancies.
A clinically important question is what types of cancer
would benefit most from ani-Dll4 therapy. Thus far,
tumor vascular Dll4 expression has been detected in
many human tumor samples including kidney, bladder,
colon, brain and breast cancer [11,25-29]. Predictive bio-
markers produced by the tumor or expressed within the
tumor vessels that confer sensitivity to Dll4-Notch
blockade have not yet been identified. A useful starting
point may be to assume that high levels of Dll4-Notch
are correlated with sensitivity to pathway inhibition [50].
Thus, further analysis of the expression levels of various
components of the Delta-Notch signaling pathway in
clinical specimens will be useful.
Inhibition of VEGF signaling was the first clinically
approved therapy targeting angiogenesis in cancer. Anti-
VEGF therapy has widespread activity against multiple
tumor types, but the effects are variable and incremen-
tal, and acquired or innate resistance is frequently
encountered [70,71]. Anti-VEGF therapy acts to prune
vascular sprouts and reduce new vessel growth [32,72],
in contrast to the cellular effects of blocking Dll4-Notch
described above. Importantly, preclinical studies have
shown that blockade of Dll4 can have potent growth
inhibitory effects on tumors that are resistant to anti-
VEGF therapies [24,30]. Furthermore, the simultaneous
targeting of Dll4 and VEGF has produced additive anti-
tumor effects compared to single agents in a number of
tumor models ([30]; Kirshner and Thurston, unpub-
lished). These observations clearly raise the possibility of
combining anti-angiogenic therapies against these two
pathways. Although blocking one pathway might sensi-
tize tumor vessels to inhibition of the other, much
remains to be learned at the mechanistic levels as to
how these two pathways interact during tumor vascular-
ization; certainly not all of the above findings can be
explained by a simple linear VEGF-Dll4-Notch4 feed-
back loop as described in the retinal angiogenesis model
[20,22].
The preclinical evaluation of combining Dll4 inhibi-
tion and cytotoxic agents represents another area of
great clinical importance. Blockade of VEGF exhibits
clinical potency predominantly when combined with
chemo- or radiation therapy. Preclinical studies have
suggested a model in which the normalization of tumor
vessels achieved by anti-VEGF therapy allows for more
efficient delivery of oxygen and drug into the tumor
[73]. Although blockade of Dll4 results in an abnormali-
zation of the tumor vasculature, combining Dll4 inhibi-
tion with cytotoxic chemotherapy frequently results in
enhanced anti-tumor activity in preclinical tumor mod-
els ([68]; Kirshner and Thurston, unpublished). In addi-
tion to the anti-angiogenic mechanism of action of
disrupting Dll4 in the tumor vasculature, direct effects
on the frequency of tumor initiating cells (cancer stem
cells) and tumor growth have been described for tumor
cell-specific targeting of Dll4 alone or in combination
with chemotherapy [68]. Additional studies are war-
ranted to elucidate the mechanism of this combination
therapy approach and to ascertain the clinical validity of
this treatment option.
Effects of Dll4-Notch blockade on normal organs
Dll4 is strongly upregulated in tumor endothelium com-
pared to normal organs, however it is expressed to some
degree in smaller arteries and capillaries of normal tis-
sues, as well as in the thymic stroma and the gastroin-
testinal tract [10,13,25-27]. The differential expression
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preferential targeting of Dll4-expressing tumor endothe-
lial cells in preclinical tumor models. However, clinical
development of Dll4 inhibitors requires careful evalua-
tion of possible adverse effects to establish a formal
therapeutic index.
In addition to a role in tumor angiogenesis, Dll4-
Notch signaling also plays a crucial role in T-cell lym-
phocyte development and differentiation. Gene targeting
studies have demonstrated that Notch1 is the essential
Notch receptor for T-cell lineage commitment, while
Dll4 is the Notch ligand required to induce Notch sig-
naling in thymic immigrant cells and to actively deter-
mine T-cell fate [74-76]. Dll4 is constitutively expressed
on the thymic epithelial cells (TEC) as well as on
endothelial cells [13,24]. Specific deletion of Dll4 in thy-
mic epithelial cells throughout development results in a
complete block of T-cell development, associated with
thymic acellularity and ectopic appearance of immature
B cells [75,76]. Subsequent studies using pharmacologic
blockade of Dll4 demonstrated that ongoing Dll4-Notch
signaling is required for T-cell differentiation in the
adult murine thymus [77]. These latter studies also
demonstrated the reversibility of the thymus/T-cell phe-
notype upon cessation of treatment with anti-Dll4 anti-
body, which has important implications for potential
clinical use of Dll4-Notch inhibitors.
A recent report demonstrated that chronic Dll4 block-
ade induced vascular proliferation in liver of mice, rats,
and monkeys with associated hepatocellular changes, as
well as the development of subcutaneous vascular
lesions in rats, referred to as neoplasia [78,79]. In
genetic mouse models, loss of Dll4 or Notch1 function
also led to the activation of liver endothelial cells and
the formation of hepatic vascular lesions [40,80],
although lesions in the skin were not reported. Of note,
vascular lesions in liver induced by anti-Dll4 antibody
administration appeared to be highly dose-dependent
[78,79]. The most pronounced effects were observed at
the highest doses, which may be beyond what is needed
for blocking Dll4 in tumor vessels in clinical settings.
Further, the effects on liver function were shown to be
reversible following cessation of treatment [79]. It will
be important to assess whether similar pathological
changes are observed with doses of anti-Dll4 antibody
that are clinically relevant.
In one study, the hepatic vascular alterations observed
in the Dll4 loss of function mice could be prevented by
concomitant treatment with the EphrinB2 signaling inhi-
bitor sEphB4-Alb. Interestingly, the simultaneous block-
ade of these signaling pathways displayed additive
inhibitory effects on pancreatic tumor growth and perfu-
sion [40]. The role of EphrinB2 in this study is consis-
tent with its recently described function as an inhibitor
of VEGF signaling in endothelial tip cells upstream of
Dll4-Notch [59,60]. This raises the intriguing possibility
that the induction of vascular changes in some organs
can be manipulated by combination anti-angiogenesis
therapy, while at the same time additive anti-tumor
effects are achieved.
Concluding Remarks and Future Directions
The endothelial cell Notch ligand Dll4 has recently
emerged as a critical regulator and a promising target in
tumor angiogenesis. Blockade of Dll4-Notch signaling in
tumors results in excessive, non-productive angiogenesis
and inhibitory effects on tumor growth. Thus inhibition
of Dll4 functions by a very different anti-angiogenic
mechanism than therapies targeting the VEGF pathway.
Significantly, enhanced anti-tumor effects in preclinical
models have been observed by combined inhibition of
Dll4 and VEGF, and blockade of Dll4 was found to have
potent growth inhibitory effects on some tumors that
are resistant to VEGF inhibition.
From a mechanistic perspective, several important
questions require further elucidation. Specifically, the
mechanisms underlying the reduced tumor vascular
perfusion induced by Dll4-Notch inhibition remain
unclear. For example, what are the primary upstream
events that lead to reduced tumor perfusion, and what
are the effects on endothelial cell polarization and
lumen formation? The characterization of signaling
pathways other than VEGF that either act upstream to
regulate Dll4 expression or downstream to mediate the
effects of Dll4-Notch signaling also warrants further
study. From a therapeutic standpoint, it will be instru-
mental to identify the tumor types that will benefit
most from ani-Dll4 therapy and to further validate
combination approaches with anti-angiogenic and che-
motherapeutic regimens. Additionally, the careful eva-
luation of adverse effects on normal organ homeostasis
for therapeutically-relevant doses of Dll4 inhibitors will
be critical for advancement of Dll4 blocking agents in
the clinic.
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